Exagen (XGN) Expected to Announce Quarterly Earnings on Tuesday

Exagen (NASDAQ:XGN) is expected to release its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $16.9010 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:30 AM ET.

Exagen Stock Down 0.8%

Exagen stock opened at $11.67 on Monday. The stock’s 50 day moving average price is $10.61 and its 200 day moving average price is $8.39. The company has a market cap of $256.74 million, a PE ratio of -13.11 and a beta of 1.66. Exagen has a 1-year low of $2.38 and a 1-year high of $12.23. The company has a debt-to-equity ratio of 1.06, a current ratio of 4.95 and a quick ratio of 4.95.

Insiders Place Their Bets

In other Exagen news, CEO John Aballi sold 31,787 shares of the firm’s stock in a transaction that occurred on Thursday, October 16th. The stock was sold at an average price of $11.82, for a total transaction of $375,722.34. Following the completion of the sale, the chief executive officer owned 714,427 shares in the company, valued at $8,444,527.14. This trade represents a 4.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 12.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Exagen

A number of hedge funds have recently bought and sold shares of the business. Balyasny Asset Management L.P. acquired a new stake in Exagen during the 2nd quarter valued at approximately $5,017,000. Russell Investments Group Ltd. acquired a new stake in Exagen during the 2nd quarter valued at approximately $1,540,000. Manatuck Hill Partners LLC acquired a new stake in Exagen during the 2nd quarter valued at approximately $1,222,000. Massar Capital Management LP grew its stake in Exagen by 715.7% during the 2nd quarter. Massar Capital Management LP now owns 170,000 shares of the company’s stock valued at $1,187,000 after purchasing an additional 149,160 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Exagen by 45.6% during the 2nd quarter. Geode Capital Management LLC now owns 146,483 shares of the company’s stock valued at $1,023,000 after purchasing an additional 45,884 shares in the last quarter. Institutional investors and hedge funds own 75.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on XGN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Exagen in a research note on Wednesday, October 8th. BTIG Research upped their price target on Exagen from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Canaccord Genuity Group upped their price target on Exagen from $11.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. KeyCorp upped their price target on Exagen from $12.00 to $15.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 14th. Finally, Craig Hallum initiated coverage on Exagen in a research note on Wednesday, July 23rd. They set a “buy” rating and a $12.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.33.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).